newsfilter
← Latest News
Business Wire·

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Phase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients Updated JANX007 data from Phase 1a dose escalation support initiation of Phase 1b dose expansion Enrollment ongoing for JANX007 and